ERP-Lab 台大醫院精神部 神經生理研究室

ERP, MMN, P50, schizophrenia, prodrome, MEG

UCSD的Braff/Light/Rissling團隊 與SCCN的Scott Makeig團隊2014新作品出版!

Cortical substrates and functional correlates of auditory deviance processing deficits in schizophrenia    Rissling AJ, Miyakoshi M, Sugar CA, Braff DL, Makeig S, Light GA.刊登於一本新的期刊Neuroimage Clin. 2014 Oct 1;6:424-37

NeuroImage: ClinicalThe new online only, open access, peer reviewed journal in clinical neuroimaging.



Gregory Light研究團隊的2014 MMN/P3a新作

Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: Characterization of demographic, clinical, cognitive, and functional correlates in COGS-2   Schizophrenia Research  Articles in Press




























Mismatch negativity (MMN) and P3a are auditory event-related potential (ERP) components that show robust deficits in schizophrenia (SZ) patients and exhibit qualities of endophenotypes, including substantial heritability, test–retest reliability, and trait-like stability. These measures also fulfill criteria for use as cognition and function-linked biomarkers in outcome studies, but have not yet been validated for use in large-scale multi-site clinical studies. This study tested the feasibility of adding MMN and P3a to the ongoing Consortium on the Genetics of Schizophrenia (COGS) study. The extent to which demographic, clinical, cognitive, and functional characteristics contribute to variability in MMN and P3a amplitudes was also examined. Participants (HCS n = 824, SZ n = 966) underwent testing at 5 geographically distributed COGS laboratories. Valid ERP recordings were obtained from 91% of HCS and 91% of SZ patients. Highly significant MMN (d = 0.96) and P3a (d = 0.93) amplitude reductions were observed in SZ patients, comparable in magnitude to those observed in single-lab studies with no appreciable differences across laboratories. Demographic characteristics accounted for 26% and 18% of the variance in MMN and P3a amplitudes, respectively. Significant relationships were observed among demographically-adjusted MMN and P3a measures and medication status as well as several clinical, cognitive, and functional characteristics of the SZ patients. This study demonstrates that MMN and P3a ERP biomarkers can be feasibly used in multi-site clinical studies. As with many clinical tests of brain function, demographic factors contribute to MMN and P3a amplitudes and should be carefully considered in future biomarker-informed clinical studies.

Schizophrenia, Mismatch negativity, P300, P3a, Cognition, Function, EEG

老化、MMN與information processing



(摘錄自 Rissling and Light et al., 2010)

(摘錄自 Rissling and Light et al., 2010)


澳洲University of Newcastle的Todd/Michie/Ward/Catts研究團隊

Mismatch negativity (MMN) reduction in schizophrenia-impaired prediction–error generation, estimation or salience?

International Journal of Psychophysiology 02/2012; 83(2):222-31.


1.Prediction, perception and agency.  Friston K. (繼續閱讀…)

MMN, P3a與不同疾病

Jahshan C, Wynn JK, Mathis KI, Altshuler LL, Glahn DC, Green MF. Cross-diagnostic comparison of duration mismatch negativity and P3a in bipolar disorder and schizophrenia. Bipolar Disord 2012: 14: 239-248.

背景介紹:印度籍的Jahshan長期擔任UCSD的Kristin Cadenhead的研究助理,進行ERP收案。 (繼續閱讀…)

幻聽, 抽煙與三種MMN

DJ Fisher與VJ Knott之加拿大研究團隊刊登於PsychiatryResearch 2012; 196(2-3)Pages 181–187的文章Nicotine and the hallucinating brain: Effects on mismatch negativity (MMN) in schizophrenia (繼續閱讀…)

MMN乃是精神分裂症的trait marker

  1. (事實上:Endophenotype的 定義本身: 就是符合Trait Marker啦):在慢性病患、未用藥的病患、初次發作的病患、未發病的一級親屬、分裂病性人格疾患者身上,都可以發現MMN之缺損,顯示MMN異常可能來自於共同的遺傳因素,是一種trait marker
  2. Umbricht et al. (1998) found an association of clozapine treatment with a significant increase of P300 amplitude, but no affection for MMN—>因此MMN might serve as a trait marker of schizophrenia
  3. Anke Brockhaus-Dumke研究團隊於Biological Psychiatry 69(10)的新文章 Prediction of Psychosis by Mismatch Negativity
    1. Mismatch negativity (MMN) was investigated in a sample clinically at high risk, comparing individuals with and without subsequent conversion to psychosis. (繼續閱讀…)


英國研究團隊於2012年January出版在Schizophrenia Research; 134(1)Pages 42–48的Reduced mismatch negativity predates the onset of psychosis

  1. 41 cases meeting PACE criteria for the At Risk Mental State (ARMS) and 50 controls performed a duration-deviant MMN. The amplitude of the MMN wave was compared between groups using linear regression. The ARMS subjects were then followed for 2 years to determine their clinical outcome.
  2. The MMN amplitude was significantly reduced in the ARMS group compared to controls. (繼續閱讀…)

Ultra-High-Risk vs. Schizophrenia Subjects之MMN

看看這一篇韓國Jun Soo Kwon研究團隊2012出版在Schizophrenia Bulletin 38(6)1258-1267的Aberrant Auditory Processing in Schizophrenia and in Subjects at Ultra-High-Risk for Psychosis

  1. This study evaluated the sensitivity of MEG N1m, N1m adaptation, and magnetic counterpart of MMN (MMNm) in 16 UHR subjects, 15 schizophrenia patients, and 18 healthy controls (HCs) during a passive auditory oddball task.
  2. 只有Deficits in auditory sensory memory[MMNm], similarly impaired in both (Ultra-High-Risk vs. Schizophrenia) groups. 而MEG N1m, N1m adaptation則在兩組間,有所差別

再看2012年Biological Psychiatry; 71(2),對於當期下面的一篇澳洲研究團隊大作之評論In Search of Psychosis Biomarkers in High-risk Populations: Is the Mismatch Negativity the One We’ve Been Waiting for? (繼續閱讀…)

P50 是State Marker?還是Trait Marker?

認為P50是trait marker的文章非常多:在慢性病患、未用藥的病患、初次發作的病患、未發病的一級親屬、分裂病性人格疾患者身上,都可以發現P50 suppression之缺損。這些缺損型態相似,而且各組之差異不大,顯示P50 suppression異常可能來自於共同的遺傳因素,是一種trait marker

  1. Sensory Gating Deficits Assessed by the P50 Event-Related Potential in Subjects With Schizotypal Personality Disorder.Kristin S. Cadenhead, M.D.; Gregory A. Light, B.A.; Mark A. Geyer, Ph.D.; David L. Braff, M.D.
  2. Coon H, Plaetke R, Holik J, et al.: Use of a neurophysiological trait in linkage analysis of schizophrenia. Biol Psychiatry 1993;34:277-289.
  3. (事實上:Endophenotype的 定義本身: 就是符合Trait Marker啦)

total of 2101304 visits